Table 2.
Demographic and clinical characteristics
| Pt | Age | Gender | serology | Symptoms | Weight loss (lb) | Electrolyte abnormality | Marsh grade/IELs | TPN | steroids | HLA | Hospital stay | Time to recover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 34 | F | tTG 113 | D | 15 | Acidosis | 3b/50 | + | + | DQ 8 | 7 days | 8 weeks |
| 2 | 51 | M | tTG >200 EMA + | D | 20 | ↓Ca, ↓K, ↓Na, ↓Alb, Acidosis, ARF (Cr- 3.1) | 3c/50 | + | + | DQ 2 | 11 days | 20 weeks |
| 3 | 48 | F | IgA def. tTG 0 | V, D, Orthostasis | 30 | ↓Ca, ↓K | 3b* | _ | _ | DQ 2 | 4 days, 3 days | 40 weeks |
| 4 | 70 | M | tTG >100 | V, D, ↑HR Abd. pain, | 10 | ↓K | 3a* | _ | _ | NA | NA | 24 weeks |
| 5 | 48 | F | NA | D, ↑HR, Neuropathy | 21 | NA | 3a/50 | _ | _ | DQ 2 | 7days | NA |
| 6 | 68 | F | tTG 6 (ref. 0 – 5) | V, D, ↓BP | 30 | ↓K, ↑Na ↓Alb | 3a* | + | + | DQ 2 | 5 days | 32 weeks |
| 7 | 67 | F | tTG 250 | D, ↓BP | 28 | ↓Ca, ↓Alb | 3c/100 | - | - | DQ2 | 8 days | 30 weeks |
| 8 | 74 | F | tTG 24.5 | D, Tetany | 30 | ↓Ca, ↓K, ↓Mg ↓Alb | 3c/60 | - | + | NA | 7 days | 8 weeks |
| 9 | 65 | M | tTG 21.3 EMA+ | D, Tetany | 20 | ↓Ca | 3a/40 | + | - | DQ2 | 10 days | 16 weeks |
| 10 | 68 | M | tTG 117 EMA+ | D, Tetany | 20 | ↓Ca, ↓Alb | 3b/60 | + | - | DQ2 | 11 days | 24 weeks |
| 11 | 65 | F | tTG 22 | D | 40 | ↓Ca, ↓Mg, Acidosis, ARF (Cr. 2.6) | 3c/80 | - | + | DQ2 | 13 days | 24 weeks |
| 12 | 49 | F | tTG 83.7 EMA+ | D | 10 | ↓Mg | 3a/50 | - | + | DQ2 | 4 days | 24 weeks |
↓ - decrease, ↑- increase, Abd. Pain- abdominal pain, Acidosis- metabolic acidosis, Alb- albumin, ARF- acute renal failure, BP- blood pressure, Ca- calcium, Cr- creatinine, D- diarrhea, EMA- endomysial antibody, F-female, HLA- human leukocyte antigen, HR- heart rate, IELs- number of intraepithelial lymphocytes per 100 epithelial cells, *-IEL count not available, IgA def.- Immunoglobulin A deficiency, K- potassium, lb- pounds, M- male, Mg- magnesium, Na- sodium, NA- not available, Orthostasis- orthostatic changes, TPN- total parenteral nutrition, V- vomiting, tTG- IgA anti-tissue transglutaminase antibody